Cingulate Inc (CING)
NASDAQ:CING
Want to see CING full AI Analyst Report?
CING Stock Chart & Stats
$5.45
-$0.31(-6.60%)
At close: 4:00 PM EST
$5.45
-$0.31(-6.60%)
Day’s Range― - ―
52-Week Range$3.16 - $11.89
Previous CloseN/A
Volume136.88K
Average Volume (3M)190.99K
Market Cap
$65.73M
Enterprise Value$8.11M
Total Cash (Recent Filing)$25.89M
Total Debt (Recent Filing)$7.43M
Price to Earnings (P/E)―
Beta5.13
Next Earnings
Aug 18, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.02
Shares Outstanding13,469,036
10 Day Avg. Volume270,731
30 Day Avg. Volume190,985
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.40
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market Cap0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$23.25Price Target Upside326.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.37
Revenue Forecast (FY)$3.63M
Bulls Say, Bears Say
Bulls Say
Strengthened U.S. Patent ProtectionA company-owned U.S. patent extending protection to 2042 provides durable exclusivity for CTx-1301’s formulation and use. This strengthens commercialization optionality, supports long-term pricing and licensing leverage, and raises barriers to generic entrants across the ADHD market.
Global IP And Platform CoverageBroad geographic patent coverage around the Precision Timed Release (PTR) platform creates a structural competitive advantage. It supports a multi-market commercialization strategy, enhances partnering/licensing appeal, and underpins expansion of a pipeline into ADHD and related CNS indications.
Access To Equity Capital (ATM Program)An ATM program providing up to $100M of issuance capacity gives durable financing flexibility to fund CMC remediation, resubmission and pre-commercial activities without needing discrete debt facilities. This reduces short-term liquidity shock risk and supports continued development into 2027.
Bears Say
Regulatory Delay From FDA Complete Response LetterA CMC-focused Complete Response Letter materially delays the NDA approval timeline and pushes commercialization further out. It requires manufacturing remediation and resubmission, increasing cash burn and timeline uncertainty, and meaningfully affects near-term path to revenue and partner discussions.
No Revenue And Multi-year Operating LossesYears of zero product revenue and recurring operating losses mean the company is wholly reliant on external financing to sustain operations. This structural revenue absence elevates dilution and refinancing risk and limits internal funding ability for development or commercialization efforts over the medium term.
High Leverage And Historical Balance Sheet InstabilityA high debt-to-equity profile and past negative equity indicate elevated capital-structure risk. In a no-revenue, pre-commercial position, leverage increases fixed obligations and reduces strategic flexibility, raising the probability of dilutive financing or constrained partnership terms over 2–6 months.
Cingulate Inc News
CING FAQ
What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $3.16 and its highest was $11.89 in the past 12 months.
What is Cingulate Inc’s market cap?
Cingulate Inc’s market cap is $65.73M.
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s upcoming earnings report date is Aug 18, 2026 which is in 62 days.
How were Cingulate Inc’s earnings last quarter?
Cingulate Inc released its earnings results on May 14, 2026. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.52 by -$0.43.
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Undervalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate is -0.63.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 13,469,036 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Cingulate Inc reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.52. Following the earnings report the stock price went down -10.772%.
Which hedge fund is a major shareholder of Cingulate Inc?
Currently, no hedge funds are holding shares in CING
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cingulate Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.25 (326.61% Upside)
$23.25 (326.61% Upside)
Hedge Fund Trend
Decreased
By 97.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $490.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.59%
12-Months-Change
Fundamentals
Return on Equity
-365.16%
Trailing 12-Months
Asset Growth
147.50%
Trailing 12-Months
Company Description
Cingulate Inc
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
CING Stock 12 Month Forecast
Average Price Target
$23.25
▲(326.61% Upside)
Technical Analysis
Bio Green Med Solution
―
NanoViricides
―
Enlivex
―
FibroBiologics, Inc.
―
Boundless Bio Inc.
―
Ownership Overview
1.93% Insiders
2.80% Mutual Funds
1.00% Other Institutional Investors
92.03% Public Companies and
Individual Investors